Immunotherapy of Hepatocellular Carcinoma
Springer International Publishing (Verlag)
978-3-319-64957-3 (ISBN)
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical "inflammation-induced" cancer.
Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
Dr. Greten is an expert in GI Oncology and tumor immunology. His specific research focus is liver cancer and immunology. He is trying to better understand how tumors in the liver interact with the immune system. Dr. Greten has his received his training in Medical Oncology, Gastroenterology and Hepatology in Germany and has been performing basic and translational research studies in tumor immunology for more than 20 years. He is currently studying novel immune based approaches to treat patients with primary hepatobiliary tumors and patients with tumors of the GI tract metastasizing into the liver.
lt;p>Introduction:
Tim F. Greten NCI, Bethesda,USA
1. Vaccine approaches
Luigi Buonagro, Naples, Italy
2. NK cell response in Hepatocellular Carcinoma
Gabriele Missale, Parma, Italy
3. Antigen-specific T cell responses in HCC
Shuichi Kaneko, Kanazawa, Japan
4. Immune checkpoint inhibitors for the treatment of HCC
Bruno Sangro, Nevarra, Spain
5. Cytokine activated killer cells for the treatment of patients with HCC
Jung-Hwan Yoon, Seoul, Korea
6. Sorafenib as a partner for immune based therapy approaches in HCC
Dan Duda, Harvard, Boston, USA
7. Glypican 3 as a target for immune based therapies in HCC
Mitchel Ho, NCI, Bethesda, USA
8. Suppressor cells and mechanisms in HCC
Tim Greten and Firouzeh Korangy, NCI, Bethesda,USA
9. Cytokines in alcoholic liver disease and HCC
Faoud Lafdil and Bin Gao
Index
| Erscheinungsdatum | 28.10.2017 |
|---|---|
| Zusatzinfo | X, 167 p. 19 illus., 15 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Gewicht | 428 g |
| Themenwelt | Medizin / Pharmazie ► Studium |
| Schlagworte | Biomedical and Life Sciences • Biomedicine general • hepatocellular carcinoma • Immune-based treatment • immunotherapy • Liver Cancer • Medical Research • tumor immunology |
| ISBN-10 | 3-319-64957-4 / 3319649574 |
| ISBN-13 | 978-3-319-64957-3 / 9783319649573 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
